Neurological Biomarkers Market Report by Type, Application, End Use, and Region 2024-2032
세계 신경 바이오마커 시장 규모는 2023년 89억 달러에 달했습니다. 향후 IMARC 그룹은 2032년까지 시장 규모가 2024-2032년간 11.3%의 연평균 성장률(CAGR)을 기록하며 2032년까지 240억 달러에 달할 것으로 예상하고 있습니다.
신경 바이오마커는 혈액이나 뇌척수액(CSF)에 존재하는 분자로, 뇌질환의 진단을 돕고 질환의 진행을 모니터링하는 역할을 합니다. 이러한 바이오마커의 주요 원천은 유전자 돌연변이, 대사산물 수준, 뇌 영상, 단백질 발현 및 번역 후 변형의 변화입니다. 바이오마커는 실험 약물에 대한 생물학적 반응을 감지하고 치료 중재를 위한 새로운 표적을 발견하는 데 도움이 되기 때문에 신경 바이오마커는 의약품 개발 중 임상에서 널리 사용되고 있습니다. 현재 연구자들은 바이오마커 농도를 측정하여 비침습적 검사, 조기 진단 및 맞춤 치료법을 제공합니다.
뇌졸중, 운동신경질환(MND), 알츠하이머병(AD), 파킨슨병(PD), 헌팅턴병(HD)과 같은 신경질환의 발생이 증가함에 따라 보다 신속한 의약품 개발의 필요성이 증가하고 있습니다. 바이오마커는 신약과 치료 전략의 효과를 측정하는 데 도움이 되기 때문에 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한, 최소 침습 수술과 개인 맞춤형 의료의 채택이 증가하고 있는 것도 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다. 이와는 별도로, 다양한 신경 질환이 표준 특징을 공유하기 때문에 특정 질환과 그 하위 유형을 구별하기 위해 여러 바이오마커에 대한 수요가 증가하고 있습니다. 또한, 질량 분석과 영상 진단의 발전으로 대량의 생화학 마커와 뇌의 구조적 변화를 신속하게 평가할 수 있게 되었습니다. 이는 디지털 바이오마커의 채택과 임상시험 증가와 함께 향후 몇 년동안 시장 성장을 가속할 것으로 예상됩니다.
본 보고서에서 다룬 주요 질문들
- 세계 신경 바이오마커 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
- 코로나19는 세계 신경 바이오마커 시장에 어떤 영향을 미쳤을까?
- 주요 지역 시장은?
- 유형별 시장 분석은?
- 용도별 시장 분석은?
- 최종 용도별 시장 현황은?
- 산업 가치사슬의 다양한 단계는?
- 업계의 주요 촉진요인과 과제는?
- 세계 신경 바이오마커 시장 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 신경 바이오마커 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 유형별
- 유전체 바이오마커
- 프로테옴 바이오마카
- 대사체학 바이오마커
- 이미징 바이오마커
- 기타
제7장 시장 분석 : 용도별
- 알츠하이머병
- 파킨슨병
- 다발성 경화증
- 자폐증 스펙트럼 장애
- 기타
제8장 시장 분석 : 최종 용도별
제9장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Abbott Laboratories
- Acumen Pharmaceuticals Inc.
- Athena Diagnostics(Quest Diagnostics)
- Banyan Biomarkers Inc.
- Bio-Rad Laboratories Inc.
- Immunarray Pvt. Ltd.
- Myriad Rbm Inc.(Myriad Genetics Inc.)
- Proteome Sciences Plc
- Thermo Fisher Scientific Inc.
LSH
The global neurological biomarkers market size reached US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.
Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.
The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end use.
Breakup by Type:
Genomic Biomarkers
Proteomic Biomarkers
Metabolomic Biomarkers
Imaging Biomarkers
Others
Breakup by Application:
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Autism Spectrum Disorders
Others
Breakup by End Use:
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global neurological biomarkers market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global neurological biomarkers market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Neurological Biomarkers Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Genomic Biomarkers
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Proteomic Biomarkers
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Metabolomic Biomarkers
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Imaging Biomarkers
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Application
- 7.1 Alzheimer's Disease
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Parkinson's Disease
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Multiple Sclerosis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Autism Spectrum Disorders
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospital Laboratories
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinical Diagnostic Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Organizations
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Acumen Pharmaceuticals Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Athena Diagnostics (Quest Diagnostics)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Banyan Biomarkers Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Bio-Rad Laboratories Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Immunarray Pvt. Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.8 Proteome Sciences Plc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Thermo Fisher Scientific Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
